Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by WealthShield Partners LLC

WealthShield Partners LLC grew its holdings in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 7.9% during the 3rd quarter, Holdings Channel reports. The firm owned 16,191 shares of the medical research company’s stock after buying an additional 1,180 shares during the period. WealthShield Partners LLC’s holdings in Edwards Lifesciences were worth $1,338,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Lazard Asset Management LLC boosted its stake in Edwards Lifesciences by 680.2% in the 2nd quarter. Lazard Asset Management LLC now owns 50,916 shares of the medical research company’s stock worth $4,840,000 after buying an additional 44,390 shares during the last quarter. Stock Yards Bank & Trust Co. acquired a new stake in Edwards Lifesciences in the 2nd quarter worth about $373,000. J.W. Cole Advisors Inc. boosted its stake in Edwards Lifesciences by 4.7% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 3,521 shares of the medical research company’s stock worth $335,000 after buying an additional 157 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Edwards Lifesciences by 19.0% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 5,381,049 shares of the medical research company’s stock worth $511,685,000 after buying an additional 860,313 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter worth about $761,000. 80.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research analyst reports. Mizuho dropped their price objective on Edwards Lifesciences from $100.00 to $85.00 and set a “buy” rating for the company in a report on Wednesday, December 7th. Cowen cut their target price on Edwards Lifesciences from $125.00 to $100.00 in a research report on Friday, October 28th. Canaccord Genuity Group cut their target price on Edwards Lifesciences from $106.00 to $91.00 and set a “hold” rating on the stock in a research report on Friday, October 14th. TheStreet lowered Edwards Lifesciences from a “b-” rating to a “c+” rating in a research report on Friday, November 4th. Finally, Citigroup cut their target price on Edwards Lifesciences from $99.00 to $92.00 and set a “buy” rating on the stock in a research report on Monday, December 12th. Eight investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $98.14.

Insider Activity

In related news, VP Daveen Chopra sold 4,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $78.00, for a total value of $312,000.00. Following the sale, the vice president now directly owns 18,911 shares in the company, valued at approximately $1,475,058. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the business’s stock in a transaction on Tuesday, November 8th. The stock was sold at an average price of $68.46, for a total transaction of $460,393.50. Following the sale, the vice president now directly owns 62,561 shares of the company’s stock, valued at $4,282,926.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daveen Chopra sold 4,000 shares of the business’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $78.00, for a total value of $312,000.00. Following the sale, the vice president now directly owns 18,911 shares in the company, valued at $1,475,058. The disclosure for this sale can be found here. In the last three months, insiders sold 91,800 shares of company stock valued at $6,933,324. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 3.7 %

Shares of Edwards Lifesciences stock opened at $77.11 on Wednesday. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $131.10. The company has a market capitalization of $47.67 billion, a PE ratio of 33.24, a P/E/G ratio of 2.78 and a beta of 1.03. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.83 and a quick ratio of 3.00. The business has a 50-day moving average of $75.55 and a 200-day moving average of $85.05.

Edwards Lifesciences (NYSE:EWGet Rating) last issued its quarterly earnings data on Thursday, October 27th. The medical research company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.01). The business had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.34 billion. Edwards Lifesciences had a net margin of 27.20% and a return on equity of 24.75%. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Further Reading

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.